Brazil Approves New Cannabidiol Formulations for Medical Use

Brazil's health agency Anvisa has approved two new formulations of Canabidiol Farmanguinhos, a medical-grade CBD product developed by the Oswaldo Cruz Foundation. Both presentations maintain the same concentration and volume as the original formulation, with the key difference being the inclusion of different dosing syringes for improved patient administration. This approval expands access to pharmaceutical-grade cannabidiol for Brazilian patients with medical indications, reflecting the country's ongoing commitment to standardizing cannabis-derived therapeutics. The regulatory advancement supports healthcare providers in delivering consistent, precise dosing of CBD to patients who may benefit from cannabinoid therapy.